XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue- Incyte Corporation (Details)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 24 Months Ended 93 Months Ended
Aug. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jan. 31, 2022
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2017
USD ($)
performanceObligation
Dec. 31, 2018
USD ($)
Sep. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2023
USD ($)
Jul. 31, 2022
USD ($)
Collaboration And Other Agreements [Line Items]                            
Total revenues       $ 72,839,000 $ 110,708,000 $ 108,273,000 $ 130,609,000              
Deferred revenue, current       10,302,000   10,302,000   $ 16,319,000     $ 10,302,000      
Deferred revenue, net of current portion       55,840,000   55,840,000   55,503,000     55,840,000      
Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Non-refundable upfront payment                 $ 150,000,000          
Potential commercial milestone payments under agreement                 330,000,000          
Potential development and regulatory milestone payments under agreement                 210,000,000          
Development and regulatory milestones recognized $ 100,000,000             100,000,000     215,000,000      
Collaborative agreement transaction price                 $ 154,000,000          
Variable consideration recognized                   $ 4,000,000        
Number of performance obligations | performanceObligation                 2          
Gilead | Gilead First Research Program                            
Collaboration And Other Agreements [Line Items]                            
Total revenues   $ 3,300,000   0 400,000 11,000,000 2,400,000              
Deferred revenue, current       0   0   11,000,000     0      
Revenue, remaining performance obligation, amount                         $ 15,700,000  
Minimum | Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Potential proceeds from royalties (percent)                 15.00%          
Maximum | Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Potential proceeds from royalties (percent)                 24.00%          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                            
Collaboration And Other Agreements [Line Items]                            
Total revenues       3,300,000 100,000 5,100,000 300,000   $ 150,000,000          
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement                            
Collaboration And Other Agreements [Line Items]                            
Total revenues       1,000,000 500,000 1,700,000 1,400,000              
RevenuesFromCMOAgreementsMember | Incyte Corporation                            
Collaboration And Other Agreements [Line Items]                            
Non-refundable upfront payment     $ 10,000,000                      
Annual Fixed Payments     14,400,000                      
Total revenues       10,500,000 $ 3,800,000 28,400,000 $ 8,100,000              
Deferred revenue, current       0   0   $ 3,400,000     0      
RevenuesFromCMOAmendmentAgreement | Incyte Corporation                            
Collaboration And Other Agreements [Line Items]                            
Annual Fixed Payments     $ 41,700,000                      
Additional Payments                       $ 13,500,000   $ 5,100,000
Manufacturing Services | Incyte Corporation                            
Collaboration And Other Agreements [Line Items]                            
Extension term                           1 year
Revenue, remaining performance obligation, amount       $ 16,800,000   $ 16,800,000         $ 16,800,000      
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01                            
Collaboration And Other Agreements [Line Items]                            
Revenue, remaining performance obligation, expected timing of satisfaction     3 years                      
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-10-01                            
Collaboration And Other Agreements [Line Items]                            
Revenue, remaining performance obligation, expected timing of satisfaction       3 years   3 years         3 years